TD Asset Management Inc. reduced its stake in United Therapeutics Co. (NASDAQ:UTHR) by 0.1% during the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 33,178 shares of the biotechnology company’s stock after selling 40 shares during the period. TD Asset Management Inc. owned 0.07% of United Therapeutics worth $4,492,000 at the end of the most recent reporting period.

Several other institutional investors have also bought and sold shares of the company. FMR LLC increased its position in United Therapeutics by 0.3% in the fourth quarter. FMR LLC now owns 4,040,250 shares of the biotechnology company’s stock valued at $579,493,000 after buying an additional 11,842 shares during the last quarter. Palo Alto Investors LLC increased its position in United Therapeutics by 6.0% in the fourth quarter. Palo Alto Investors LLC now owns 1,868,815 shares of the biotechnology company’s stock valued at $268,044,000 after buying an additional 105,357 shares during the last quarter. LSV Asset Management increased its position in United Therapeutics by 2.9% in the third quarter. LSV Asset Management now owns 1,266,660 shares of the biotechnology company’s stock valued at $149,567,000 after buying an additional 36,010 shares during the last quarter. Bank of New York Mellon Corp increased its position in United Therapeutics by 7.2% in the first quarter. Bank of New York Mellon Corp now owns 830,555 shares of the biotechnology company’s stock valued at $112,441,000 after buying an additional 55,649 shares during the last quarter. Finally, Old Mutual Global Investors UK Ltd. increased its position in United Therapeutics by 32.7% in the first quarter. Old Mutual Global Investors UK Ltd. now owns 820,823 shares of the biotechnology company’s stock valued at $111,123,000 after buying an additional 202,479 shares during the last quarter.

Institutional Ownership by Quarter for United Therapeutics (NASDAQ:UTHR)

United Therapeutics Co. (NASDAQ:UTHR) traded up 0.99% during midday trading on Friday, reaching $119.51. 187,454 shares of the company were exchanged. The firm has a market capitalization of $5.38 billion, a PE ratio of 8.39 and a beta of 1.42. United Therapeutics Co. has a 52 week low of $97.52 and a 52 week high of $169.89. The company has a 50-day moving average of $121.95 and a 200 day moving average of $138.72.

United Therapeutics (NASDAQ:UTHR) last announced its quarterly earnings results on Wednesday, April 26th. The biotechnology company reported $3.89 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $3.12 by $0.77. United Therapeutics had a return on equity of 41.78% and a net margin of 44.40%. The company had revenue of $370.50 million during the quarter, compared to the consensus estimate of $399.59 million. During the same period in the previous year, the company posted $3.02 earnings per share. United Therapeutics’s revenue for the quarter was up .4% on a year-over-year basis. Equities analysts predict that United Therapeutics Co. will post $14.42 earnings per share for the current year.

COPYRIGHT VIOLATION NOTICE: “TD Asset Management Inc. Sells 40 Shares of United Therapeutics Co. (UTHR)” was published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are accessing this piece of content on another publication, it was stolen and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/05/26/td-asset-management-inc-sells-40-shares-of-united-therapeutics-co-uthr.html.

Several brokerages recently commented on UTHR. JPMorgan Chase & Co. set a $125.00 price objective on shares of United Therapeutics and gave the company a “hold” rating in a research note on Tuesday, April 11th. Oppenheimer Holdings Inc. set a $175.00 price objective on shares of United Therapeutics and gave the company a “buy” rating in a research note on Wednesday, February 22nd. Cowen and Company cut shares of United Therapeutics from an “outperform” rating to a “market perform” rating and reduced their price objective for the company from $140.00 to $121.00 in a research note on Monday, April 3rd. Wedbush reaffirmed an “outperform” rating and set a $229.00 price objective on shares of United Therapeutics in a research note on Tuesday, April 4th. Finally, Credit Suisse Group AG reaffirmed an “underperform” rating and set a $120.00 price objective on shares of United Therapeutics in a research note on Monday, April 3rd. Three research analysts have rated the stock with a sell rating, eight have issued a hold rating and two have given a buy rating to the company. The stock presently has an average rating of “Hold” and a consensus target price of $137.09.

In other United Therapeutics news, CEO Martine A. Rothblatt sold 1,261 shares of the business’s stock in a transaction that occurred on Thursday, May 18th. The stock was sold at an average price of $120.72, for a total value of $152,227.92. Following the completion of the transaction, the chief executive officer now directly owns 1,401 shares of the company’s stock, valued at $169,128.72. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, CEO Martine A. Rothblatt sold 1,203 shares of the business’s stock in a transaction that occurred on Thursday, March 2nd. The shares were sold at an average price of $148.49, for a total value of $178,633.47. Following the completion of the transaction, the chief executive officer now directly owns 1,343 shares of the company’s stock, valued at $199,422.07. The disclosure for this sale can be found here. Insiders sold 16,891 shares of company stock valued at $2,212,521 over the last three months. 7.50% of the stock is currently owned by corporate insiders.

United Therapeutics Company Profile

United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).

12 Month Chart for NASDAQ:UTHR

Receive News & Stock Ratings for United Therapeutics Co. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Co. and related stocks with our FREE daily email newsletter.